Boehringer Ingelheim’s phosphodiesterase 4B (PDE4B) inhibitor nerandomilast has demonstrated efficacy in a second Phase III trial, this time in patients with progressive pulmonary fibrosis (PPF). The company announced on 10 February that it will file nerandomilast with the US Food and Drug Administration and other global regulators for both PPF and idiopathic pulmonary fibrosis (IPF).
Boehringer Plans Filing For Nerandomilast After Second Phase III Hits
The PDE4B inhibitor showed improvement in lung function in patients with progressive pulmonary fibrosis in a second positive Phase III trial in pulmonary fibrosis.
More from Respiratory
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus